Delaware seeks earliest start to cannabis sales

A new bill aimed at accelerating the sale of cannabis for recreational purposes through existing health clinics has drawn both support and opposition in Delaware.

While supporters of this measure argue that it will streamline deployment and generate immediate tax revenue, its critics fear that it will unfairly benefit current operators and stifle new entrants to the market. The state of Delaware legalized cannabis in 2023.

Legislative Developments Regarding Cannabis in Delaware

A bill that could significantly accelerate the state’s progress toward the sale of recreational cannabis has been passed by a Delaware legislative committee. The House of Representatives Committee on Economic Development, Banking, Insurance, and Commerce voted in favor of a measure allowing current medical cannabis suppliers to become dual-licensed operators. This measure would allow them to serve both medical patients and adult-use consumers. sooner than originally scheduled.

The legislation, sponsored by the Democratic Representative Ed Osienski and the Senator Trey Paradee, which have played a central role in the state’s cannabis reform efforts, is proposing the creation of a «conversion license» category. This category would establish criteria allowing medical cannabis businesses to transition to a dual license. These businesses must demonstrate their ability to meet ongoing medical demand, support the state’s social equity program, and enter into a collective bargaining agreement with a recognized union.

The Representative Osienski highlighted the potential benefits of the bill, stating: «This bill will build on the existing medical program to provide a solid foundation for a successful adult-use recreational program, support the equity initiative, save time and resources, and generate tax revenue for the state in the short term.».

He also highlighted the speed of the process, predicting that recreational cannabis could be available to consumers by April 1, 2025.

Key Provisions and Requirements

Under the proposed legislation, the Delaware Office of the Marijuana Commissioner (OMC) would be required to begin accepting applications for conversion licenses before August 1, with the deadline set for November 1.

Holders of an approved conversion license could begin sales immediately upon approval, with their license expiring after four years. These companies would then have the option to apply for general licenses before the expiration date. License fees are set at $100,000, with the proceeds earmarked for financial assistance to applicants for conditional licenses under the social equity program.

Concerns Raised by Advocates

Despite the bill's potential for rapid implementation, several advocates for cannabis reform have expressed significant concerns. Zoë Patchell, executive director of the Delaware Cannabis Advocacy Network, warned that the legislation could undermine efforts to ensure fair competition and equity.

«HB 408 would set progress back by giving six lucky companies a golden ticket that no other company will get,» she said, highlighting the risk of creating an unbalanced market where existing operators have a substantial advantage.

Chris Goldstein, a regional organizer for the National Organization for the Reform of Marijuana Laws (NORML), echoes Ms. Patchell’s concerns. Mr. Goldstein points to the experience in New Jersey, where medical cannabis businesses were given priority over the recreational market.

«All the promises I’ve seen in New Jersey so far have gone unfulfilled,» he said, warning that Delaware could repeat those mistakes.

He criticized HB 408 as a prime example of «how not to do things,» suggesting that’No country has yet succeeded in implementing equity in cannabis legalization, and that Delaware’s current plan risks continuing this trend.

The Debate on Equity

The question of’social equity in the cannabis industry is also at the heart of the debate. The proposed bill stipulates that conversion license holders must support Delaware’s social equity program. However, critics argue that this provision does not go far enough to ensure true equity. They fear that allowing established companies to dominate the market from the outset will marginalize newcomers, particularly those from communities disproportionately affected by the past prohibition of cannabis.

The tension between opportunism and fairness is palpable. On the one hand, it is clearly advantageous to leverage the infrastructure and experience of existing medical dispensaries to launch recreational sales. This approach promises immediate tax revenue and a regulated supply chain. On the other hand, it raises concerns about equity and the potential entrenchment of existing players, which could stifle innovation and inclusivity in a rapidly growing market.